Download PDF
Semin Thromb Hemost 2024; 50(08): 1163-1172
DOI: 10.1055/s-0044-1787189
Review Article

Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents

Geoffrey Kershaw
1   Institute of Haematology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, Australia
2   ANZAC Research Institute, University of Sydney, Hospital Road, Concord, NSW, Australia
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

For several decades, therapeutic options for inherited deficiencies of factor VIII or IX (hemophilia A or B, respectively) have largely been the replacement of the missing clotting factor with plasma-derived or recombinant products. Hemostasis laboratories use standard activated partial thromboplastin time (aPTT)-based clotting or chromogenic assays to monitor plasma factor levels to guide therapy. The emergence in the past 10 years of extended half-life replacement products and other novel therapies for hemophilia has led to a reappraisal of assay suitability, with studies of product measurement showing some existing assay types or reagents to be unsuitable for some products. The hemostasis laboratory must adapt to the changing landscape by adding new assays or modifying existing assays to ensure accurate results for product measurement. These strategies include switching from a chromogenic assay to a clotting assay, or vice versa, changing an aPTT reagent brand, or introducing product specific calibrators. This article evaluates the effects of some of the newer treatment options on the laboratory testing of factor levels and related assays.

Keywords

emicizumab - Mim8 - rpFVIII - efanesoctocog alfa - FVIII


Publication History

Article published online:
12 June 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost 2020; 18 (06) 1242-1255
    CrossrefPubMedGoogle Scholar
  • 2 Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost 2023; 21 (03) 403-412
    CrossrefPubMedGoogle Scholar
  • 3 Abraham S, Duncan EM. A review of factor VIII and factor IX assay methods for monitoring extended half-life products in hemophilia A and B. In: Favaloro E, Gosselin R. eds. Hemostasis and Thrombosis Methods and Protocols. 2nd ed. 2023: 569-588
    Google Scholar
  • 4 Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 2017; 43 (03) 331-337
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Zanon E, Pasca S, Borchiellini A. et al. Susoctocog-alfa (Obizur®) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. Blood Transfus 2020; 18 (04) 312-321
    PubMedGoogle Scholar
  • 6 Lauritzen B, Bjelke M, Björkdahl O. et al. A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys. J Thromb Haemost 2022; 20 (06) 1312-1324
    CrossrefPubMedGoogle Scholar
  • 7 Kitazawa T, Esaki K, Tachibana T. et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117 (07) 1348-1357
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Muto A, Yoshihashi K, Takeda M. et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124 (20) 3165-3171
    CrossrefPubMedGoogle Scholar
  • 9 Muto A, Yoshihashi K, Takeda M. et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2014; 12: 206-213
    CrossrefPubMedGoogle Scholar
  • 10 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
    CrossrefPubMedGoogle Scholar
  • 11 Oldenburg J, Mahlangu JN, Bujan W. et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25 (01) 33-44
    CrossrefPubMedGoogle Scholar
  • 12 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 13 Shima M, Hanabusa H, Taki M. et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374 (21) 2044-2053
    CrossrefPubMedGoogle Scholar
  • 14 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost 2019; 119 (09) 1384-1393
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Bowyer A, Kitchen S, Maclean R. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia 2020; 26 (03) 536-542
    CrossrefPubMedGoogle Scholar
  • 16 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Jenkins PV, Bowyer A, Burgess C. et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' organisation guideline. Haemophilia 2020; 26 (01) 151-155
    CrossrefPubMedGoogle Scholar
  • 18 Schmitt C, Emrich T, Chebon S. et al. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia 2021; 27 (06) 984-992
    CrossrefPubMedGoogle Scholar
  • 19 Kershaw G, Dix C. Measuring emicizumab levels in the hemostasis laboratory. In Favaloro E, Lippi G. eds. Hemostasis and Thrombosis Methods and Protocols. 2nd ed. New York:: Springer Science.; 2023. 2663. 589-595
    Google Scholar
  • 20 Kershaw G, Dix C, Chen VM, Cai N, Khoo TL. Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement. Pathology 2022; 54 (06) 755-762
    CrossrefPubMedGoogle Scholar
  • 21 Bowyer AE, Maclean RM, Kitchen S. The combination of emicizumab and recombinant factor VIII in plasma: which assays can we use for accurate measurement?. Int J Lab Hematol 2023; 45 (03) 368-376
    CrossrefPubMedGoogle Scholar
  • 22 Shima M, Amano K, Ogawa Y. et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost 2023; 21 (03) 534-545
    CrossrefPubMedGoogle Scholar
  • 23 Hamedani NS, Donners AAMT, van Luin M. et al. Functional determination of emicizumab in presence of factor VIII activity. J Thromb Haemost 2023; 21 (12) 3490-3500
    CrossrefPubMedGoogle Scholar
  • 24 Persson P, Amstrup AB, Coester HV, Matytsina I, Bas S. Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. Res Pract Thromb Haemost 2023; 7 (06) 102181
    CrossrefPubMedGoogle Scholar
  • 25 Seremetis SV, Clausen WHO, Matytsina I, Nissen SM, Wåhlander K. Mim8 clinical development program: an overview of the frontier studies. Blood 2022; 140 (Suppl. 01) 5630-5631
    CrossrefPubMedGoogle Scholar
  • 26 Lentz SR, Chowdary P, Gil L. et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, PK, and PD of Mim8, a factor VIIIa mimetic. J Thromb Haemost 2024; 22 (04) 990-1000
    CrossrefPubMedGoogle Scholar
  • 27 Bowyer AE, Kitchen S, Ezban M. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation. J Thromb Haemost 2023; 21 (03) 480-487
    CrossrefPubMedGoogle Scholar
  • 28 Bowyer AE, Hickey K, Kitchen S, Ezban M. A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non-factor VIII related haemostasis assays. Haemophilia 2023; 29 (06) 1633-1637
    CrossrefPubMedGoogle Scholar
  • 29 Lillicrap D, Schiviz A, Apostol C. et al. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia 2016; 22 (02) 308-317
    CrossrefPubMedGoogle Scholar
  • 30 Kruse-Jarres R, Kempton CL, Baudo F. et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 2017; 92 (07) 695-705
    CrossrefPubMedGoogle Scholar
  • 31 Kruse-Jarres R, St-Louis J, Greist A. et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21 (02) 162-170
    CrossrefPubMedGoogle Scholar
  • 32 Fosbury E, Drebes A, Riddell A, Chowdary P. Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A. Ther Adv Hematol 2017; 8 (09) 263-272
    CrossrefPubMedGoogle Scholar
  • 33 Turecek PL, Romeder-Finger S, Apostol C. et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia 2016; 22 (06) 957-965
    CrossrefPubMedGoogle Scholar
  • 34 Vanguru VR, Kershaw G, Konda M, Chen VM. Laboratory monitoring issues in recombinant porcine FVIII replacement in acquired haemophilia A. Haemophilia 2018; 24 (02) e70-e74
    CrossrefPubMedGoogle Scholar
  • 35 Pipe S, Sadeghi-Khomami A, Konkle BA. et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia 2024; 30 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 36 Konkle BA, Shapiro AD, Quon DV. et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med 2020; 383 (11) 1018-1027
    CrossrefPubMedGoogle Scholar
  • 37 Seth Chhabra E, Liu T, Kulman J. et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood 2020; 135 (17) 1484-1496
    CrossrefPubMedGoogle Scholar
  • 38 von Drygalski A, Chowdary P, Kulkarni R. et al; XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388 (04) 310-318
    CrossrefPubMedGoogle Scholar